Top Markets
Coin of the day
Delta-Fly Pharma, Inc. Delta-Fly Pharma, Inc.

Delta-Fly Pharma, Inc.

4598
Clasificación en acciones #32530
Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a... Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a biotechnology company focused on the development of innovative oncology drugs. Their comprehensive pipeline includes several drug candidates targeting various cancers. DFP-10917 is currently undergoing Phase III clinical evaluation in the United States and Phase I in Japan for relapsed/refractory acute myeloid leukemia. Another significant compound, DFP-14323, is in Phase III trials for lung cancer. The firm is also advancing DFP-17729 through Phase I/II studies for solid tumors. Furthermore, DFP-11207 has successfully completed its Phase I clinical trial for pancreatic cancer. For hematologic malignancies, DFP-14927 is in Phase I, while DFP-10825 is in preclinical development, targeting gastric and ovarian cancers.
Precio por acción
$0.69158324
Capitalización bursátil
$9.84M
Cambio (1 día)
0.00%
Cambio (1 año)
-84.15%
País
JP
Comercio Delta-Fly Pharma, Inc. (4598)

Categoría

Ratio P/B de Delta-Fly Pharma, Inc. (4598)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Delta-Fly Pharma, Inc., el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de Delta-Fly Pharma, Inc. desde 2026 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
Not enough data for the provided dates.
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
6.3419 -
US
6.2413 -
NL
- -
CH
- -
KR
3.4612 -
BE